Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

New partnership aims to advance vaccine against MERS coronavirus CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop VTP-500

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then...